Sage Therapeutics, Inc. (SAGE)

Sage Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	72.32	163.97	295.5	1,663	129.07
Short-Term Investments	682.19	1,110	1,448	438.47	881.69
Cash & Cash Equivalents	754.52	1,274	1,744	2,101	1,011
Cash Growth	-40.76%	-26.94%	-17.02%	107.89%	9.25%
Receivables	83.01	13.66	18.51	0	0
Other Current Assets	31.83	49.56	38.57	21.11	24.33
Total Current Assets	869.35	1,337	1,801	2,122	1,035
Property, Plant & Equipment	6.38	13.43	19.13	31.82	42.9
Other Long-Term Assets	6.55	6.04	5.52	5.06	6.16
Total Long-Term Assets	12.93	19.47	24.65	36.88	49.06
Total Assets	882.28	1,356	1,825	2,159	1,084
Accounts Payable	10.32	18.95	10.45	3.69	15.27
Current Debt	5.17	7.64	7.47	8.66	10.24
Other Current Liabilities	67.26	72.67	67.28	54.85	86.62
Total Current Liabilities	82.75	99.26	85.19	67.2	112.13
Long-Term Debt	0	4.49	10.96	19.44	26.85
Other Long-Term Liabilities	0	0.1	0.1	0.27	0.52
Total Long-Term Liabilities	0	4.59	11.06	19.71	27.37
Total Liabilities	82.75	103.85	96.26	86.91	139.5
Total Debt	5.17	12.13	18.43	28.1	37.09
Debt Growth	-57.43%	-34.17%	-34.41%	-24.24%	-
Retained Earnings	-2,569.66	-2,028.17	-1,495.39	-1,037.49	-1,643.57
Comprehensive Income	-0.81	-10.21	-2.66	0.42	1.3
Shareholders' Equity	799.53	1,253	1,729	2,072	944.66
Net Cash / Debt	749.35	1,262	1,725	2,073	973.67
Net Cash / Debt Growth	-40.60%	-26.87%	-16.79%	112.92%	5.25%
Net Cash Per Share	12.52	21.27	29.40	39.11	19.15
Working Capital	786.6	1,238	1,715	2,055	922.97
Book Value Per Share	13.36	21.12	29.47	39.87	18.58

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).